Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis

Hiroki Yabe, Tomohide Tsukahara, Satoshi Kawaguchi, Takuro Wada, Noriyuki Sato, Hideo Morioka, Hiroo Yabe

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Ewing's sarcoma family of tumors (ESFT) is comprised of highly malignant bone and soft tissue tumors in children and young adults. Despite intensive treatments for patients with ESFT, disease which presents with metastatic spread or relapses after primary treatment remains incurable in the majority of cases, indicating the importance of efforts to develop new treatment modalities, including immunotherapy. The present study was designed to examine the expression profile of papillomavirus binding factor (PBF), which we previously defined as an osteosarcoma-associated antigen, and its prognostic significance for patients with ESFT. Biopsy specimens from 20 ESFT were stained with an anti-PBF antibody. Survival was estimated using Kaplan-Meier plots and the prognostic significance of several variables, including the expression status of PBF, on disease-free and overall survival was determined by univariate analysis using the log-rank test. Of 20 specimens, 18 (90%) reacted positively to the anti-PBF antibody. Fifteen specimens (75%) were graded as PBF overexpression. Of the 11 variables analyzed, stage III disease, inadequate surgical margins and PBF overexpression were significantly associated with decreased disease-free and overall survival. None of the other variables, including age, gender, origin of tumor, tumor site or levels of LDH, ALP, CRP and ESR, showed any significant association. These findings indicate that the overexpression of PBF is a factor indicative of poor prognosis in ESFT. PBF may also serve as a putative target antigen in immunotherapy for patients with ESFT that have a poor prognosis and PBF overexpression.

Original languageEnglish
Pages (from-to)129-134
Number of pages6
JournalOncology Reports
Volume19
Issue number1
Publication statusPublished - 2008 Jan

Fingerprint

Ewing's Sarcoma
Neoplasms
Immunotherapy
Disease-Free Survival
Antibodies
Young Adult
Therapeutics
Biopsy
Antigens
Bone and Bones
Recurrence
Survival

Keywords

  • Ewing's sarcoma family of tumor
  • Immunohistochemistry
  • Papillomavirus binding factor
  • Prognostic factor
  • Tumor-associated antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Yabe, H., Tsukahara, T., Kawaguchi, S., Wada, T., Sato, N., Morioka, H., & Yabe, H. (2008). Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis. Oncology Reports, 19(1), 129-134.

Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis. / Yabe, Hiroki; Tsukahara, Tomohide; Kawaguchi, Satoshi; Wada, Takuro; Sato, Noriyuki; Morioka, Hideo; Yabe, Hiroo.

In: Oncology Reports, Vol. 19, No. 1, 01.2008, p. 129-134.

Research output: Contribution to journalArticle

Yabe, H, Tsukahara, T, Kawaguchi, S, Wada, T, Sato, N, Morioka, H & Yabe, H 2008, 'Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis', Oncology Reports, vol. 19, no. 1, pp. 129-134.
Yabe H, Tsukahara T, Kawaguchi S, Wada T, Sato N, Morioka H et al. Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis. Oncology Reports. 2008 Jan;19(1):129-134.
Yabe, Hiroki ; Tsukahara, Tomohide ; Kawaguchi, Satoshi ; Wada, Takuro ; Sato, Noriyuki ; Morioka, Hideo ; Yabe, Hiroo. / Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis. In: Oncology Reports. 2008 ; Vol. 19, No. 1. pp. 129-134.
@article{c3d7dbc37d28429f882357cc98345556,
title = "Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis",
abstract = "Ewing's sarcoma family of tumors (ESFT) is comprised of highly malignant bone and soft tissue tumors in children and young adults. Despite intensive treatments for patients with ESFT, disease which presents with metastatic spread or relapses after primary treatment remains incurable in the majority of cases, indicating the importance of efforts to develop new treatment modalities, including immunotherapy. The present study was designed to examine the expression profile of papillomavirus binding factor (PBF), which we previously defined as an osteosarcoma-associated antigen, and its prognostic significance for patients with ESFT. Biopsy specimens from 20 ESFT were stained with an anti-PBF antibody. Survival was estimated using Kaplan-Meier plots and the prognostic significance of several variables, including the expression status of PBF, on disease-free and overall survival was determined by univariate analysis using the log-rank test. Of 20 specimens, 18 (90{\%}) reacted positively to the anti-PBF antibody. Fifteen specimens (75{\%}) were graded as PBF overexpression. Of the 11 variables analyzed, stage III disease, inadequate surgical margins and PBF overexpression were significantly associated with decreased disease-free and overall survival. None of the other variables, including age, gender, origin of tumor, tumor site or levels of LDH, ALP, CRP and ESR, showed any significant association. These findings indicate that the overexpression of PBF is a factor indicative of poor prognosis in ESFT. PBF may also serve as a putative target antigen in immunotherapy for patients with ESFT that have a poor prognosis and PBF overexpression.",
keywords = "Ewing's sarcoma family of tumor, Immunohistochemistry, Papillomavirus binding factor, Prognostic factor, Tumor-associated antigen",
author = "Hiroki Yabe and Tomohide Tsukahara and Satoshi Kawaguchi and Takuro Wada and Noriyuki Sato and Hideo Morioka and Hiroo Yabe",
year = "2008",
month = "1",
language = "English",
volume = "19",
pages = "129--134",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis

AU - Yabe, Hiroki

AU - Tsukahara, Tomohide

AU - Kawaguchi, Satoshi

AU - Wada, Takuro

AU - Sato, Noriyuki

AU - Morioka, Hideo

AU - Yabe, Hiroo

PY - 2008/1

Y1 - 2008/1

N2 - Ewing's sarcoma family of tumors (ESFT) is comprised of highly malignant bone and soft tissue tumors in children and young adults. Despite intensive treatments for patients with ESFT, disease which presents with metastatic spread or relapses after primary treatment remains incurable in the majority of cases, indicating the importance of efforts to develop new treatment modalities, including immunotherapy. The present study was designed to examine the expression profile of papillomavirus binding factor (PBF), which we previously defined as an osteosarcoma-associated antigen, and its prognostic significance for patients with ESFT. Biopsy specimens from 20 ESFT were stained with an anti-PBF antibody. Survival was estimated using Kaplan-Meier plots and the prognostic significance of several variables, including the expression status of PBF, on disease-free and overall survival was determined by univariate analysis using the log-rank test. Of 20 specimens, 18 (90%) reacted positively to the anti-PBF antibody. Fifteen specimens (75%) were graded as PBF overexpression. Of the 11 variables analyzed, stage III disease, inadequate surgical margins and PBF overexpression were significantly associated with decreased disease-free and overall survival. None of the other variables, including age, gender, origin of tumor, tumor site or levels of LDH, ALP, CRP and ESR, showed any significant association. These findings indicate that the overexpression of PBF is a factor indicative of poor prognosis in ESFT. PBF may also serve as a putative target antigen in immunotherapy for patients with ESFT that have a poor prognosis and PBF overexpression.

AB - Ewing's sarcoma family of tumors (ESFT) is comprised of highly malignant bone and soft tissue tumors in children and young adults. Despite intensive treatments for patients with ESFT, disease which presents with metastatic spread or relapses after primary treatment remains incurable in the majority of cases, indicating the importance of efforts to develop new treatment modalities, including immunotherapy. The present study was designed to examine the expression profile of papillomavirus binding factor (PBF), which we previously defined as an osteosarcoma-associated antigen, and its prognostic significance for patients with ESFT. Biopsy specimens from 20 ESFT were stained with an anti-PBF antibody. Survival was estimated using Kaplan-Meier plots and the prognostic significance of several variables, including the expression status of PBF, on disease-free and overall survival was determined by univariate analysis using the log-rank test. Of 20 specimens, 18 (90%) reacted positively to the anti-PBF antibody. Fifteen specimens (75%) were graded as PBF overexpression. Of the 11 variables analyzed, stage III disease, inadequate surgical margins and PBF overexpression were significantly associated with decreased disease-free and overall survival. None of the other variables, including age, gender, origin of tumor, tumor site or levels of LDH, ALP, CRP and ESR, showed any significant association. These findings indicate that the overexpression of PBF is a factor indicative of poor prognosis in ESFT. PBF may also serve as a putative target antigen in immunotherapy for patients with ESFT that have a poor prognosis and PBF overexpression.

KW - Ewing's sarcoma family of tumor

KW - Immunohistochemistry

KW - Papillomavirus binding factor

KW - Prognostic factor

KW - Tumor-associated antigen

UR - http://www.scopus.com/inward/record.url?scp=38849108843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849108843&partnerID=8YFLogxK

M3 - Article

C2 - 18097586

AN - SCOPUS:38849108843

VL - 19

SP - 129

EP - 134

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -